- Home
- FTRE vs MDXG Comparison
FTRE vs MDXG Comparison
Compare FTRE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- MDXG
- Stock Information
- Founded
- FTRE 1996
- MDXG 2006
- Country
- FTRE United States
- MDXG United States
- Employees
- FTRE N/A
- MDXG N/A
- Industry
- FTRE Medical Specialities
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- FTRE Health Care
- MDXG Health Care
- Exchange
- FTRE Nasdaq
- MDXG Nasdaq
- Market Cap
- FTRE 469.0M
- MDXG 1.0B
- IPO Year
- FTRE N/A
- MDXG N/A
- Fundamental
- Price
- FTRE $5.95
- MDXG $7.42
- Analyst Decision
- FTRE Hold
- MDXG Strong Buy
- Analyst Count
- FTRE 11
- MDXG 3
- Target Price
- FTRE $18.00
- MDXG $12.00
- AVG Volume (30 Days)
- FTRE 2.3M
- MDXG 809.0K
- Earning Date
- FTRE 05-12-2025
- MDXG 04-30-2025
- Dividend Yield
- FTRE N/A
- MDXG N/A
- EPS Growth
- FTRE N/A
- MDXG N/A
- EPS
- FTRE N/A
- MDXG 0.27
- Revenue
- FTRE $2,696,400,000.00
- MDXG $352,375,000.00
- Revenue This Year
- FTRE N/A
- MDXG $9.23
- Revenue Next Year
- FTRE $3.32
- MDXG $11.49
- P/E Ratio
- FTRE N/A
- MDXG $27.33
- Revenue Growth
- FTRE N/A
- MDXG 5.34
- 52 Week Low
- FTRE $4.77
- MDXG $5.47
- 52 Week High
- FTRE $37.24
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- FTRE 43.28
- MDXG 59.64
- Support Level
- FTRE $5.40
- MDXG $6.53
- Resistance Level
- FTRE $6.38
- MDXG $7.07
- Average True Range (ATR)
- FTRE 0.45
- MDXG 0.30
- MACD
- FTRE 0.21
- MDXG 0.09
- Stochastic Oscillator
- FTRE 72.52
- MDXG 99.61
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.